Ryan Moy: Our investigator-initiated trial for diffuse gastric cancer after progression on first-line therapy is now open at Columbia!

Ryan Moy, Assistant Professor of Medicine and Medical Oncologist at Columbia University Irving Medical Center, made the following post on X:

“Our investigator-initiated trial targeting the FAK and MAPK pathways with defactinib and avutometinib for patients with diffuse gastric cancer after progression on first-line therapy is now open at Columbia!”

Read the article.
Source: Ryan Moy/X
.